Deadline: 14-Jul-2026
The Pfizer Research Grant Request for Proposals (RFP) supports real-world evidence (RWE) research evaluating whether early treatment with ritlecitinib leads to improved clinical outcomes for patients with alopecia areata. U.S.-based organizations can apply for grants of up to USD 100,000 for projects lasting up to 24 months to investigate treatment timing, disease progression, and patient outcomes.
Pfizer Research Grant for Real-World Evidence in Early Ritlecitinib Treatment for Alopecia Areata
What is the Pfizer Research Grant?
The Pfizer Research Grant Request for Proposals (RFP) is designed to support independent research that generates real-world evidence (RWE) on the effectiveness of early initiation of ritlecitinib in treating alopecia areata.
The programme seeks to determine whether starting treatment earlier in the disease course leads to improved clinical outcomes compared with delayed treatment or conventional treatment pathways. The findings are expected to enhance understanding of treatment timing and inform future clinical decision-making.
Programme Objectives
The grant aims to:
- Generate real-world evidence on early treatment with ritlecitinib.
- Compare early versus delayed treatment initiation.
- Improve understanding of disease progression in alopecia areata.
- Identify patient characteristics associated with better treatment outcomes.
- Support evidence-based clinical decision-making.
- Strengthen knowledge of treatment pathways for severe alopecia areata.
About Alopecia Areata
What is Alopecia Areata?
Alopecia areata is a chronic immune-mediated disease that causes non-scarring hair loss.
The condition affects approximately 2% of the global population and may involve partial or complete hair loss on the scalp and other parts of the body. In severe cases, alopecia areata can significantly affect emotional well-being, self-confidence, and quality of life.
Recent therapeutic advances have expanded treatment options, including the approval of ritlecitinib for severe alopecia areata in adults and adolescents aged 12 years and older.
Research Priority Areas
Applications should address one or more of the following priorities.
Early vs. Delayed Treatment
Evaluate whether initiating ritlecitinib early produces better outcomes than delayed treatment.
Real-World Evidence
Use real-world clinical data to assess:
- Treatment effectiveness
- Patient outcomes
- Healthcare utilization
- Long-term disease management
Clinical Outcomes
Research may evaluate:
- Hair regrowth
- Disease progression
- Treatment response
- Quality of life
- Long-term effectiveness
Treatment Pathways
Compare:
- Early intervention
- Conventional treatment approaches
- Delayed initiation strategies
Predictive Factors
Identify patient and disease characteristics that predict improved response to early treatment.
Background
The grant builds upon findings from the ALLEGRO Phase 2b/3 clinical programme, which supported the approval of ritlecitinib for severe alopecia areata.
Emerging analyses suggest that patients with:
- Shorter disease duration
- Lower baseline disease severity
may experience improved treatment outcomes when therapy begins earlier. The programme seeks additional real-world evidence to further investigate these observations.
Funding Information
Grant Amount
Applicants may request funding of up to:
- USD 100,000 per project
Project Duration
Projects may last up to:
- 24 months
Who is Eligible?
The funding opportunity is open to organizations located in the United States.
Eligible organizations include research institutions capable of conducting independent clinical or observational research.
Individuals are not eligible to receive funding directly.
Principal Investigator Requirements
The Principal Investigator (PI) must:
- Be located in the United States.
- Be employed by or contracted with the requesting organization.
- Hold an eligible professional qualification.
Acceptable qualifications include:
- MD
- PhD
- Equivalent doctoral degree
- Advanced nursing degree
- Pharmacy degree
- Physiotherapy degree
- Social Work degree
Organizational Requirements
The requesting organization must:
- Be legally able to receive grant funding from Pfizer Inc.
- Play a substantive role in the proposed project.
- Clearly define the responsibilities of all participating institutions if multiple organizations are involved.
Independent medical practice groups and individual applicants are not eligible.
Why This Research Matters
Although effective treatments for alopecia areata are now available, important questions remain regarding the optimal timing of treatment initiation.
This research initiative aims to:
- Improve evidence-based treatment decisions.
- Better understand disease progression.
- Identify patients most likely to benefit from early intervention.
- Improve long-term clinical outcomes.
- Reduce the psychosocial burden associated with severe alopecia areata.
- Support future clinical practice and research.
How to Apply
Step 1: Confirm Eligibility
Verify that:
- The organization is based in the United States.
- The PI meets all qualification requirements.
Step 2: Develop the Research Proposal
Prepare a study focused on:
- Early versus delayed treatment
- Real-world evidence
- Clinical outcomes
- Disease progression
- Predictive patient characteristics
Step 3: Prepare the Project Plan
Include:
- Study objectives
- Research methodology
- Data sources
- Timeline
- Expected outcomes
Step 4: Develop the Budget
Prepare a detailed budget not exceeding USD 100,000.
Step 5: Submit the Application
Complete the application and submit all required documentation according to the RFP guidelines.
Tips for a Strong Proposal
Applicants should:
- Clearly explain the research question.
- Use robust real-world data sources.
- Demonstrate scientific rigor.
- Include measurable clinical outcomes.
- Present a realistic project timeline.
- Explain the relevance of early treatment.
- Show how the findings will improve patient care.
Common Mistakes to Avoid
Avoid:
- Submitting proposals without a clear real-world evidence methodology.
- Exceeding the funding limit.
- Failing to explain the clinical importance of treatment timing.
- Providing incomplete study designs.
- Using unrealistic project timelines.
- Applying as an individual rather than through an eligible organization.
- Omitting the qualifications of the Principal Investigator.
Frequently Asked Questions (FAQs)
1. What is the purpose of this Pfizer Research Grant?
The grant supports real-world evidence research investigating whether early initiation of ritlecitinib improves clinical outcomes in patients with alopecia areata.
2. How much funding is available?
Each research project may receive up to USD 100,000.
3. How long can funded projects last?
Projects may have a maximum duration of 24 months.
4. Who can apply?
Eligible applicants are organizations located in the United States. Individual researchers and independent medical practice groups are not eligible to apply directly.
5. What research topics are encouraged?
Priority topics include early versus delayed treatment, disease progression, treatment effectiveness, predictive patient characteristics, and real-world clinical outcomes.
6. Who can serve as the Principal Investigator?
The PI must be affiliated with the requesting organization and hold an eligible qualification such as an MD, PhD, advanced nursing degree, or a degree in Pharmacy, Physiotherapy, or Social Work.
7. Why is early treatment with ritlecitinib being studied?
Emerging findings from the ALLEGRO Phase 2b/3 clinical programme suggest that patients with shorter disease duration and lower baseline severity may achieve better outcomes with earlier treatment. This grant seeks to validate these findings using real-world evidence.
Conclusion
The Pfizer Research Grant Request for Proposals offers U.S.-based research organizations an opportunity to generate valuable real-world evidence on the impact of early ritlecitinib treatment for alopecia areata. With funding of up to USD 100,000 over 24 months, the programme supports research that can improve understanding of treatment timing, identify patients most likely to benefit from early intervention, and strengthen evidence-based clinical care for this chronic immune-mediated condition.
For more information, visit Pfizer.
